Chardan Capital Reaffirms Their Buy Rating on Immunic Inc (IMUX)

By Carrie Williams

In a report released today, Taylor Feehley from Chardan Capital reiterated a Buy rating on Immunic Inc (IMUXResearch Report), with a price target of $40. The company’s shares closed on Friday at $13.01, close to its 52-week low of $6.04.

Feehley noted:

“We see this trial as potentially supportive of an accelerated path to approval/market for IMU-838, as PSC is an orphan indication, which may provide earlier revenues and/or help derisk testing of IMU-883 in larger market indications.”

According to TipRanks.com, Feehley has 0 stars on 0-5 star ranking scale with an average return of -30.1% and a 13.6% success rate. Feehley covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Kaleido Biosciences Inc, and Evelo Biosciences Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Immunic Inc with a $40 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $386 and a one-year low of $6.04. Currently, Immunic Inc has an average volume of 156K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Immunic, Inc. engages in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.